Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093795 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
A Phase 3 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,894
- Enrollment target
NCT00093795: Completed Phase 3 study, sponsored by NSABP Foundation.
NCT00093795 is a Phase 3 study that has completed, run by NSABP Foundation. The registered enrollment target is 4,894 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (534% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093795, a Phase 3 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,894 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.
Primary Outcome
The percentage of patients alive and cancer-free.
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,894 participants |
| Start Date | 2004-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
What the finished NCT00093795 record still lists
NCT00093795 is an interventional study that assigns participants to a tested intervention. Its 4,894 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (534% higher).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00093795 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00093795 about?
NCT00093795 is a clinical study titled "Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This...
What is the current status of trial NCT00093795?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,894 participants. The study started on 2004-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT00093795?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00093795?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00093795's enrollment target sits among peer trials
4,894 52nd of 2000 higher than 1,949 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05929976 · 4,900 participants
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
- NCT05252754 · 4,874 participants · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
- NCT05485675 · 4,800 participants · NA
Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia